We and others have shown in vitro that treatment with exogenous IFN-β (type I IFN) or IFN-λ1 (type III IFN) induces a long-lasting antiviral state in respiratory epithelial cells and reduces infection with viruses like HRV33–35. Here, IFNB1 is linked to infection.